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The efforts of many to increase the awareness of cardiovasculardisease in women have focused on the primary killer: coronaryartery disease. Unlike acquired coronary disease, valvular diseasetends to affect women in all age groups and may particularly pose aserious problem in women of childbearing age. Given the simplicityof such screening methods as cardiac auscultation and transthoracic
echocardiogram, more women with previously undiagnosed valvular disease can be
identified, and guidelines for follow-up and treatment, when necessary, can be
recommended. We will review the surgical issues of valvular heart disease that are
specific to women during the childbearing and postmenopausal years.
Aortic Valve
Significant aortic stenosis (AS) is not common during the childbearing years. In this
age group, stenotic lesions are most commonly congenital in origin in the Western
world and are due to rheumatic disease in developing countries. The most common
cause of AS in the postmenopausal years is senile calcification that appears in the
sixth decade for bicuspid valves or the seventh decade for tricuspid valves. Medical
therapy has little role in the management of AS. Any woman with symptoms of AS,
including congestive heart failure, syncope, or angina, should have aortic valve
replacement (AVR). With improvement in surgical outcomes, there is a trend
toward earlier referral for AVR. Asymptomatic women with aortic valve areas 1
cm2 or smaller should be considered for AVR, especially younger women who
anticipate future pregnancy.
Aortic insufficiency (AI) during the childbearing years is most commonly asso-
ciated with endocarditis or Marfan syndrome and related connective tissue disor-
ders. In older women with AI the cause is usually hypertensive aortic dilatation or
mixed AS/AI lesions of calcific valves. There is a significant role for medical
therapy in AI because the risk of sudden death is very low in asymptomatic patients.
However, these women require regular surveillance with echocardiography and
education for awareness of symptoms. Women with AI are more likely than men to
have significant symptoms before ventricular enlargement is noted. Consequently,
women more often have class III or IV symptoms at operation and have a similar
early outcome but poorer late survival than with men.1 Because ventricular enlarge-
ment is a late finding in women and is associated with poor long-term survival,
women with 3 AI or greater should be considered for AVR only with class II
symptoms. Once symptoms are apparent, left ventricular (LV) deterioration may
proceed rapidly. Any impairment of LV function, LV dilatation, or an increase in
LV end-diastolic pressure warrants thorough evaluation and consideration for AVR.
Generally the issues concerning the choice of valve prosthesis—mechanical
versus biologic—are similar with both genders. However, outcomes for AVR vary
significantly between men and women.1,2 When corrected for body size, women
have smaller aortic roots that more often require root enlargement or result in a
patient-prosthetic mismatch with incomplete remodeling of the hypertrophic ven-
tricle.3,4 Despite a similar degree of LV outflow tract obstruction, women have a
smaller end-systolic chamber size, generate higher pressures, and are more likely to
have postoperative hypertrophic cardiomyopathy than men.5 The 30-day and late
mortality after AVR for AS is higher in women,2 particularly if concomitant
coronary artery bypass grafting is necessary.
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Mitral Valve
Mitral valve prolapse is the most common valvular disease
and affects an estimated 6% of all women. It is unusual in
its gender-specific age distribution. Mitral valve prolapse is
commonly diagnosed in young women, and the incidence
decreases dramatically in older women. This differs from
the incidence in men, which is relatively constant across all
age groups.6,7 Approximately 60% of patients with mitral
valve prolapse have no symptoms, and most of these will
never need treatment. Asymptomatic patients with mitral
valve prolapse and more than mild mitral regurgitation
should be identified, and appropriate surveillance should be
established. Antibiotic prophylaxis for dental or other inva-
sive procedures should be recommended.8 Annual exami-
nation that reveals a change in murmur or a presentation of
dyspnea or chronic fatigue warrants valve interrogation by
echocardiogram.
Rheumatic fever is rarely seen today in developed coun-
tries; hence, the incidence of mitral stenosis (MS) has de-
creased except in areas with large immigrant populations.
Women comprise more than 70% of MS cases.9 Although
asymptomatic MS lesions rarely necessitate intervention,
women with a mitral valve area of 1.5 cm2 or smaller should
consider intervention if they plan to have children.
Pregnancy
The interaction between pregnancy and valvular heart dis-
ease is complex; each affects the other. The hemodynamic
changes that occur during pregnancy are well described.
Tachycardia and increased intravascular volume begin in
the sixth week and increase rapidly until the fourth or fifth
month.10 Anemia may result from an unbalanced increase in
plasma volume over erythrocyte mass. Tachycardia, in-
creased intravascular volume, and increased cardiac output
combine to increase the resting gradient across a stenotic
valve up to double. These changes increase volume over-
load on the heart in regurgitant lesions, worsening heart
failure symptoms. Previously asymptomatic, undiagnosed
valvular lesions may be unmasked by hemodynamic
changes in pregnancy. If the valvular lesion is not severe,
the patient may be medically managed through her preg-
nancy, and more definitive therapy may be delayed. How-
ever, severe valvular disease threatens the mother’s well-
being and increases the risk of fetal loss.
Successful valve replacement or repair during pregnancy
has been described.11 The use of cardiopulmonary bypass
during pregnancy does not increase the maternal mortality
risk, but fetal mortality has been reported as 12% to 20%.12
Teratogenesis risk is greatest in the first trimester, and
spontaneous abortion risk is greatest during the third trimes-
ter.12 Therefore, the optimum timing if operation cannot be
avoided is during the second trimester.
Successful cardiac operations necessitate preoperative
planning and preparation for optimal intraoperative man-
agement by the entire heart team. Special concerns include
hypothermia during bypass, which can increase the chance
of fetal bradycardia and death, and anesthetics, which may
have teratogenic effects. The mother’s blood pressure needs
to be monitored closely during bypass to ensure effective
placental perfusion, and the use of a fetal heart monitor is
recommended.
Certainly the best option is to address valvular heart
disease before pregnancy. Avoidance of pregnancy is an
option, but this is not acceptable to many young women. If
a valve operation is undertaken during pregnancy, special
consideration should be given to the procedure of choice.
The preferred option for patients who meet valve structural
criteria is balloon valvuloplasty, which may benefit patients
with either MS or AS in their second or third trimesters of
pregnancy. For those women who are not candidates for
valvuloplasty, procedures that do not require long-term an-
ticoagulation are the first choice. Mitral valve repair is
favored over replacement.
Warfarin sodium (Coumadin) crosses the placenta with a
15% to 25% incidence of fetal malformations, including
facial and digital abnormalities, optic atrophy, and mental
impairment. Heparin or low-molecular-weight heparin can
be used, but the optimal dosing regimen is unclear. Aspirin
therapy alone is probably safe in pregnancy but is less
effective in preventing thromboembolic complications.13
The safety of other antiplatelet therapy such as ticlopidine,
clopidogrel, or glycoprotein IIb/IIIa inhibitors is unproven
in pregnancy.
Pregnant women receiving long-term anticoagulation (ie,
for prosthetic mechanical valves or atrial fibrillation) may
be placed on a regimen of heparin for the first trimester,
followed by warfarin. One week before expected delivery,
warfarin should be stopped and heparin resumed. Srivastava
and colleagues14 reported an alternative approach after
studying 32 pregnancies of mothers who remained on war-
farin until the week before anticipated delivery, at which
time they were switched to heparin. Of these, 6% had
spontaneous abortions, 3% had premature births, and 91%
progressed to full term. There were no episodes of throm-
boembolism or valve thrombosis, and all mothers survived.
A skeletal deformity (nasal hypoplasia) was present in 10%
of the babies.
Turner Syndrome
Turner syndrome is a genetic abnormality of phenotypic
females. The karyotype may be monosomy (45,X), mosa-
icism of an X chromosome (X/XX or X/XXX), or a struc-
tural abnormality of the X chromosome. These women have
a higher incidence of cardiovascular anomalies than the
general population, with an incidence between 17% and
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42%.15 In the largest reported series,15 aortic valve disor-
ders were present in 18%. Bicuspid aortic valve was the
most prevalent, whereas the incidence of bicuspid aortic
valve is 1% to 2% in the general population.15 Further,
tricuspid aortic valves have a higher prevalence of both AI
and AS in individuals with Turner syndrome; this is likely
related to a mesenchymal defect in the ascending aorta.16
Echocardiographic screening for valvular disease should be
performed with periodic surveillance in all girls diagnosed
with Turner syndrome.
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